Role of Folate Antagonists in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection
The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) infection has reached epidemic proportions, and therapeutic options are limited because these strains are often multidrug resistant. However, the new strains of community-acquired MRSA show decreased resistance to trimethoprim-sulfamethoxazole. Clinical and experimental reports show a mixture of successes and failures with trimethoprim-sulfamethoxazole treatment. A reason for failure might be the amount of thymidine released from damaged host tissues and bacteria, a concept strengthened by the fact that S. aureus thermonuclease releases thymidine from DNA. Thus, success or failure with trimethoprim-sulfamethoxazole may well depend on the amount of tissue damage and organism burden, rather than acquisition of a resistance gene. Clinical trials and experimental animal studies show high failure rates, perhaps because of released thymidine. The use of trimethoprim-sulfamethoxazole for community-acquired MRSA infection should not be endorsed without further research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of trimethoprimsulfamethoxazole and other folate antagonists may be attenuated by thymidine release from damaged host cells (eg, at sites of tissue damage such as abscesses).166”
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department
Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., & Talan, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055356 · Cited by 2,285 · cited 1×
“Thus, TMP-SMZ has been suggested for treatment of MRSA infection [13, 18, 19, 26, 27] because TMP-SMZ is inexpensive, is well tolerated, and penetrates well into tissues.”
BackgroundCosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602 · cited 1×
“Thus, TMP-SMZ has been suggested for treatment of MRSA infection [13, 18, 19, 26, 27] because TMP-SMZ is inexpensive, is well tolerated, and penetrates well into tissues.”
BackgroundSelf-citationProctor, R. A., von Eiff, C., Kahl, B. C., Becker, K., McNamara, P., Herrmann, M., & Peters, G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1384 · Cited by 1,175
Self-citationEmergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Leibovici, Shraga, Drucker, Konigsberger, Samra, Pitlik, & Pitlik (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00379.x · Cited by 685
Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
Research works printed but not linked: 11
- Khawcharoenporn, 2006, Hawaii medical journal, 65, 290
- Markowitz, 1992, Annals of Internal Medicine, 117, 390, 10.1059/0003-4819-117-5-390 · doi:10.1059/0003-4819-117-5-390
- 1939, Lancet, 2, 1065
- 1939, INTL CLINICS, 4, 1
- 1938, Lancet, 2, 1233
- 1938, Lancet, 2, 1232
- TORREY, 1941, Annals of Internal Medicine, 15, 431, 10.1059/0003-4819-15-3-431 · doi:10.1059/0003-4819-15-3-431
- 1939, Lancet, 1, 756
- McDowell, 1991, Clinical laboratory science : journal of the American Society for Medical Technology, 4, 299
- FINLAND, 1942, Annals of Internal Medicine, 17, 920, 10.1059/0003-4819-17-6-920 · doi:10.1059/0003-4819-17-6-920
- Levine, 1991, Annals of Internal Medicine, 115, 674, 10.1059/0003-4819-115-9-674 · doi:10.1059/0003-4819-115-9-674
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“ated by thymidine release from damaged host cells (eg, at sites of tissue damage such as abscesses).(166) In an in vitro study,(167)”
BackgroundDavid, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Community-associated meticillin-resistant Staphylococcus aureus
DeLeo, F. R., Otto, M., Kreiswirth, B. N., & Chambers, H. F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61999-1 · Cited by 1,506
Nanotechnology as a therapeutic tool to combat microbial resistance
Pelgrift, R. Y., & Friedman, A. J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.011 · Cited by 1,432
A new strategy to fight antimicrobial resistance: the revival of old antibiotics
Cassir, N., Rolain, J.-M., & Brouqui, P. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00551 · Cited by 280
“Trimethoprim is a tetrahydrofolate reductase inhibitor that, when added to sulfamethoxazole, provides a second-step block in the folate biosynthetic pathway (Proctor, 2008).”
BackgroundBioinorganic antimicrobial strategies in the resistance era
Regiel-Futyra, A., Dąbrowski, J. M., Mazuryk, O., Śpiewak, K., Kyzioł, A., Pucelik, B., Brindell, M., & Stochel, G. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.005 · Cited by 164
Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus aureus
Lade, H., & Kim, J.-S. (2021) · Antibiotics · doi:10.3390/antibiotics10040398 · Cited by 134
Nguyen, H. M., & Graber, C. J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp377 · Cited by 132
Staphylococcus , Micrococcus , and Other Catalase-Positive Cocci
Becker, K., Skov, R. L., & von Eiff, C. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch21 · Cited by 127
Krátký, M., Vinšová, J., Volková, M., Buchta, V., Trejtnar, F., & Stolaříková, J. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.060 · Cited by 93
Welte, T., & Pletz, M. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.045 · Cited by 94
Oral antibiotic treatment of staphylococcal bone and joint infections in adults
Kim, B.-N., Kim, E. S., & Oh, M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt374 · Cited by 86
Kao, T.-T., Tu, H.-C., Chang, W.-N., Chen, B., Shi, Y.-Y., Chang, T.-C., & Fu, T.-F. (2010) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2010.04.025 · Cited by 95
Dhand, A., & Sakoulas, G. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.005 · Cited by 80
Lobo, L. J., Reed, K. D., & Wunderink, R. G. (2010) · Chest · doi:10.1378/chest.09-1562 · Cited by 72
Kriegeskorte, A., Lorè, N. I., Bragonzi, A., Riva, C., Kelkenberg, M., Becker, K., Proctor, R. A., Peters, G., & Kahl, B. C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00742-15 · Cited by 81
“Andre Kriegeskorte,a Nicola Ivan Lorè,b Alessandra Bragonzi,b Camilla Riva,b Marco Kelkenberg,a Karsten Becker,a Richard A. Proctor,c Georg Peters,a,d Barbara C. Kahla”
BackgroundSelf-citationWilliams, D. J., Cooper, W. O., Kaltenbach, L. A., Dudley, J. A., Kirschke, D., Jones, T. F., Arbogast, P. G., Griffin, M. R., & Creech, C. B. (2011) · PEDIATRICS · doi:10.1542/peds.2010-3681 · Cited by 71
Identification of Staphylococcus aureus Factors Required for Pathogenicity and Growth in Human Blood
Connolly, J., Boldock, E., Prince, L. R., Renshaw, S. A., Whyte, M. K., & Foster, S. J. (2017) · Infection and Immunity · doi:10.1128/iai.00337-17 · Cited by 62
“aureus to utilize pyrimidine salvage pathways and thus survive (41).”
Bowen, A. C., Carapetis, J. R., Currie, B. J., Fowler, V. G., Chambers, H. F. “., & Tong, S. Y. C. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx232 · Cited by 63
“Concerns have been raised that S aureus can acquire free thymidine from deoxyribonucleic acid fragments present in purulent abscess material, thus allowing S aureus to bypass the inhibitory effects of SXT on the folate synthesis pathway [50].”
BackgroundMolecular Basis of Non-β-Lactam Antibiotics Resistance in Staphylococcus aureus
Lade, H. S., Joo, H., & Kim, J. (2022) · Antibiotics · doi:10.3390/antibiotics11101378 · Cited by 74
“In general, TMP–SMX has a greater effect as a combination because synergistically they inhibit two consecutive steps in nucleic acid and protein synthesis which are critical for the growth and cell division of bacteria [276].”
BackgroundGoldberg, E., Paul, M., Talker, O., Samra, Z., Raskin, M., Hazzan, R., Leibovici, L., & Bishara, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq179 · Cited by 55
Trimethoprim-sulfamethoxazole Therapy for Children With Acute Osteomyelitis
Messina, A. F., Namtu, K. C., Guild, M., Dumois, J. A., & Berman, D. M. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31822db658 · Cited by 55
“Its use in the treatment of invasive infections has been discouraged because of concern for therapeutic failures.(11) The only randomized, double-blinded human subject trial comparing vancomycin to TMP-SMX showed inferiority of TMP-SMX in the treatment of intravenous drug users with methicillin-susceptible S.”
BackgroundDryden, M., Andrašević, A. T., Bassetti, M., Bouza, E., Chastre, J. E., Cornaglia, G., Esposito, S., French, G. L., Giamarellou, H., Gyssens, I. C., et al. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03135.x · Cited by 57
“Before the advent of CA-MRSA, trimethoprim–sulphamethoxazole was rarely used for treatment of skin infections, because of poor activity against group A streptococci [139].”
BackgroundRevisiting “Older” Antimicrobials in the Era of Multidrug Resistance
Pogue, J. M., Marchaim, D., Kaye, D., & Kaye, K. S. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.912 · Cited by 48
“This action when added to that of sulfamethoxazole, allows TMP-SMX to have bactericidal action.(35) Trimethoprim-sulfamethoxazole has long been considered the drug of choice for severe infections due to Pneumocystis jiroveci (formerly Pneumocystis carinii), Stenotrophomonas maltophilia, and Nocardia species, including…”
BackgroundCraft, J. C., Moriarty, S. R., Clark, K., Scott, D., Degenhardt, T. P., Still, J., Corey, G. R., Das, A., & FERNANDES, P. B. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir167 · Cited by 49
Hyun, D. Y., Mason, E. O., Forbes, A., & Kaplan, S. L. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181826e5e · Cited by 47
Uçkay, İ., Jugun, K., Gamulin, A., Wagener, J., Hoffmeyer, P. J., & Lew, D. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0286-0 · Cited by 45
“depend on the amount of tissue damage and organism burden [70].”
BackgroundFrey, K. M., Lombardo, M. N., Wright, D. L., & Anderson, A. C. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2009.12.011 · Cited by 45
“In addition to beta-lactam resistance, some MRSA strains are resistant to therapeutics including vancomycin and trimethoprim-sulfamethoxazole (Drew, 2007; Proctor, 2008).”
BackgroundSwain, S. S., Paidesetty, S. K., & Padhy, R. N. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.036 · Cited by 48
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections
Odell, C. A. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328339421b · Cited by 48
Antibacterial Agents in Pediatrics
Chávez‐Bueno, S., & Stull, T. L. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.011 · Cited by 45
“Most of the experience with using TMP/SMX to provide therapy for S aureus infection in children is anecdotal; therefore, more studies are needed to ascertain its efficacy as a first-line therapy in this population.(76) Adverse effects for TMP/SMX include mild to severe dermatologic conditions and various gastrointesti…”
Increasing Threat of Community-Acquired Methicillin-Resistant Staphylococcus aureus
Bukharie, H. A. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181e95fdc · Cited by 42
Viswanathan, K., Frey, K. M., Scocchera, E. W., Martin, B. D., Swain, P. W., Alverson, J. B., Priestley, N. D., Anderson, A. C., & Wright, D. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029434 · Cited by 38
“aureus (MRSA) is of particular concern, especially in the United States where the prevalence is more than 55% in the intensive care unit [1] and the incidence causes longer hospital stays, higher costs and higher risk of death [2].”
BackgroundTreatment of MRSA Infection: Where are We?
Nazli, A., Tao, W., You, H., He, X., & He, Y. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673249381231130111352 · Cited by 41
Invasive Staphylococcus aureus Infections in Children in Tropical Northern Australia
Engelman, D., Hofer, A., Davis, J. S., Carapetis, J. R., Baird, R., Giffard, P. M., Holt, D. C., & Tong, S. Y. C. (2014) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piu013 · Cited by 41
“Concerns have been raised regarding the efficacy of SXT in severe infections, in which high organism burden and tissue damage lead to release of thymidine [32].”
BackgroundGould, I. M. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70542-4 · Cited by 42
Cadena, J., Nair, S., Henao‐Martínez, A. F., Jorgensen, J. H., PATTERSON, J. E., & Sreeramoju, P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00706-11 · Cited by 39
“TMP/SMX acts against MRSA through inhibition of dihydropteroate synthase (sulfamethoxazole) and tetrahydrofolate reductase (trimethoprim), leading to impaired thymidine biosynthesis (8).”
BackgroundThe safety of treatment options for acute bacterial skin and skin structure infections
Bassetti, M., Peghin, M., Castaldo, N., & Giacobbe, D. R. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1621288 · Cited by 37
“However, some concerns exist regarding its role in the treatment of severe ABSSSI, since it exerts less rapid bactericidal activity compared with other agents such as βlactams and glycopeptides [82].”
BackgroundBesier, S., Zander, J., Siegel, E., Saum, S. H., Hunfeld, K.-P., Ehrhart, A., Brade, V., & Wichelhaus, T. A. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01440-08 · Cited by 35
Mahapatra, M., Mohapatra, P., Sahoo, S. K., Bishoyi, A. K., Padhy, R. N., & Paidesetty, S. K. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135190 · Cited by 37
Parchman, M. L., & Munoz, A. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.04.090003 · Cited by 34
Han, J., Lee, M., Kim, D., Lee, Y. H., Park, J. C., & Lee, J. (2016) · Chemosphere · doi:10.1016/j.chemosphere.2016.05.085 · Cited by 34
Staphylococcus, Micrococcus , and Other Catalase-Positive Cocci
Becker, K., & von Eiff, C. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch19 · Cited by 75
Invasive community-associated MRSA infections: epidemiology and antimicrobial management
Pichereau, S., & Rose, W. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.511614 · Cited by 31
“Proctor also demonstrated a theoretical resistance mechanism for TMP/SMX in SSTI [98].”
BackgroundTalan, D. A., LoVecchio, F., Abrahamian, F. M., Karras, D. J., Steele, M. T., Rothman, R. E., Krishnadasan, A., Mower, W. R., Hoagland, R. J., & Moran, G. J. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw177 · Cited by 33
“aureus, through its ability to release thymidine from DNA fragments present in high concentrations in pus, may antagonize the antimicrobial effects of TMP-SMX [9].”
BackgroundAntimicrobial Agents in Treatment of MRSA Infections
Johnson, M. D., & Decker, C. F. (2008) · Disease-a-Month · doi:10.1016/j.disamonth.2008.09.002 · Cited by 30
Long-term low-dose antibiotics in recalcitrant chronic rhinosinusitis: a retrospective analysis
Videler, W. J. M., van Hee, K., Reinartz, S. M., Georgalas, C., van der Meulen, F. W., & Fokkens, W. J. (2012) · Rhinology Journal · doi:10.4193/rhino11.123 · Cited by 29
Avery, L. M., Steed, M. E., Woodruff, A. E., Hasan, M. S., & Rybak, M. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01046-12 · Cited by 29
Antibiotic options for treating community-acquired MRSA
Powell, J. P., & Wenzel, R. P. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.3.299 · Cited by 33
Coordination of CcpA and CodY Regulators in Staphylococcus aureus USA300 Strains
Poudel, S., Hefner, Y., Szubin, R., Sastry, A. V., Gao, Y., Nizet, V., & Palsson, B. Ø. (2022) · mSystems · doi:10.1128/msystems.00480-22 · Cited by 28
Teixeira, M. M., Araújo, M. C., Silva-Carvalho, M. C., Beltrame, C. O., Oliveira, C. C. H. B., Figueiredo, A. M. S., & de Oliveira, A. G. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500065 · Cited by 31
“However, controlled clinical trials describing successful therapy with SXT for MRSA infections compared to VAN and other available anti-MRSA drugs are still very scarce (25).”
BackgroundMRSA Infections: From Classical Treatment to Suicide Drugs
Drebes, J., Künz, M., Pereira, C. A., Betzel, C., & Wrenger, C. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867320666131119122520 · Cited by 33
Thomsen, I. P., & Liu, G. Y. (2018) · JCI Insight · doi:10.1172/jci.insight.98216 · Cited by 30
“Metabolic and nutritional pathways The antimicrobial agents TMP and SMX inhibit necessary steps in folate synthesis (8), a key S.”
BackgroundBacterial Conversion of Folinic Acid Is Required for Antifolate Resistance*
Ogwang, S., Nguyen, H. T., Sherman, M., Bajaksouzian, S., Jacobs, M., Boom, W., Zhang, G.-F., & Nguyen, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.231076 · Cited by 28
Structure of S. aureus HPPK and the Discovery of a New Substrate Site Inhibitor
Chhabra, S., Dolezal, O., Collins, B. M., Newman, J. M., Simpson, J. S., Macreadie, I. G., Fernley, R. T., Peat, T. S., & Swarbrick, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029444 · Cited by 27
Synergistic Antimicrobial Activities of Folic Acid Antagonists and Nucleoside Analogs
Zander, J., Besier, S. M., Ackermann, H., & Wichelhaus, T. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-09 · Cited by 27
Zander, J., Besier, S. M., Faetke, S., Saum, S. H., Müller, V., & Wichelhaus, T. A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.08.007 · Cited by 26
New Antimicrobial Agents for Use in the Intensive Care Unit
Ritchie, D. J., Alexander, B. T., & Finnegan, P. M. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.010 · Cited by 25
Strategies for potentiation of ethionamide and folate antagonists againstMycobacterium tuberculosis
Wolff, K., & Nguyen, L. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.87 · Cited by 31
Clarke, R. S., Bruderer, M. S., Ha, K. P., & Edwards, A. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00944-19 · Cited by 27
“The presence in host tissues of thymidine and other folate-dependent metabolites, including serine, methionine, and glycine, has been reported previously to modulate the susceptibility of SXT-treated cells and restrict the types of infection that can be treated with this antibiotic (9).”
BackgroundMechanisms of folate metabolism-related substances affecting Staphylococcus aureus infection
Jin, Q., Xie, X., Zhai, Y., & Zhang, H. (2023) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2023.151577 · Cited by 30
Haj, C. E., Murillo, Ó., Ribera, A., Lloberas, N., Gómez‐Junyent, J., Tubau, F., Fontova, P., Cabellos, C., & Ariza, J. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.01.014 · Cited by 24
Stein, G. E., Throckmorton, J. K., Scharmen, A., Weiss, J., Prókai, L., Smith, C. L., & Havlichek, D. H. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt267 · Cited by 23
The challenge of developing robust drugs to overcome resistance
Anderson, A. C., Pollastri, M. P., Schiffer, C. A., & Peet, N. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.07.001 · Cited by 23
Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria
Kinney, K. K. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181e99aa4 · Cited by 25
Παππάς, Γ., Athanasoulia, A. P., Matthaiou, D. K., & Falagas, M. E. (2009) · Journal of Chemotherapy · doi:10.1179/joc.2009.21.2.115 · Cited by 24
Leonard, S. N., Kaatz, G. W., Rucker, L. R., & Rybak, M. J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn379 · Cited by 20
“Trimethoprim/sulfamethoxazole has been widely used for the treatment of MRSA infections in the outpatient setting though there is little data to support its use and it has been associated with failures.(25) Fluoroquinolones have shown excellent activity against S.”
BackgroundNew therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus
Bouza, E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03091.x · Cited by 29
Cunha, B. A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.08.006 · Cited by 19
Kubištová, L., Dvořáček, L., Tkadlec, J., Melter, O., & Lichá, I. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0064 · Cited by 21
“aureus can bypass the inhibitory effect of TMP-SMT by the uptake of thymidine present in the medium.(33)”
DeRonde, K., Girotto, J. E., & Nicolau, D. P. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2164 · Cited by 19
Lawrence, K. R., Golik, M. V., & Davidson, L. E. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fdea8 · Cited by 18
Egbuobi, R. C., Wachuku, C. K., Dike-Ndudim, J. N., Ogamaka, I. A., Okorie, H. M., Nwagbaraocha, M. A., AMADI, J. C., Egbuobi, L. N., & Ereh, J. E. (2014) · International Journal of Medicine and Medical Sciences · doi:10.5897/ijmms2013.1001 · Cited by 17
“One way in which Staphylococci become resistant is through acquisition of a chromosomal gene (mecA) that encodes an alternate target protein which is not inactivated by methicillin (Proctor, 2008).”
BackgroundSaleh‐Mghir, A., Dumitrescu, O., Dinh, A., Boutrad, Y., Massias, L., Martin, E. C., Vandenesch, F., Étienne, J., Lina, G., & Crémieux, A. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00926-12 · Cited by 16
“However, some of those compounds can be ineffective in vivo (32).”
BackgroundBecker, K., Kriegeskorte, A., Sunderkötter, C. H., Löffler, B., & von Eiff, C. (2014) · Der Hautarzt · doi:10.1007/s00105-013-2636-8 · Cited by 20
New therapy options for MRSA with respiratory infection/pneumonia
Ramírez, P., Fernández‐Barat, L., & Torres, A. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283509cfa · Cited by 15
“However, the effect may be antagonized by the use of exogenous thymidine and, given that this nucleoside is abundant in pus, iclaprim may not be effective in purulent infections [55].”
BackgroundSystemtherapie mit Antiinfektiva
Sunderkötter, C. H., & Becker, K. (2014) · Der Hautarzt · doi:10.1007/s00105-013-2743-6 · Cited by 14
Boccaccio, C., Babic, V. V., Botto, L., Cervetto, M. M., Cetani, S., Paladino, S., Conti, R., Lanzillota, A., Herrera, R., & Amarante, D. (2014) · PubMed · Cited by 13
Gold, H. S., & Pillai, S. K. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2008.10.008 · Cited by 17
Kime, L., Waring, T., Mohamad, M., Mann, B. F., & O’Neill, A. J. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad063 · Cited by 12
Novel Sulfonamide Derivatives as a Tool to Combat Methicillin-Resistant Staphylococcus Aureus
Krátký, M. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0116 · Cited by 21
Drekonja, D. M., Traynor, L. M., DeCarolis, D. D., Crossley, K., & Johnson, J. R. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.10.001 · Cited by 11
Audretsch, C. K., Gratani, F. L., Wolz, C., & Dandekar, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-88646-1 · Cited by 8
Sato, T., Kawamura, M., Furukawa, E., & Fujimura, S. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.05.008 · Cited by 10
Enoch, D., Karas, J. A., & Aliyu, S. H. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.014 · Cited by 10
Zander, J., Hartenfeller, M., Hähnke, V. D., Proschak, E., Besier, S. M., Wichelhaus, T. A., & Schneider, G. (2010) · Chemistry - A European Journal · doi:10.1002/chem.201001347 · Cited by 8
Uekötter, A., Peters, G., & Becker, K. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03549.x · Cited by 7
Robinson, J. L., & Salvadori, M. I. (2011) · Paediatrics & Child Health · doi:10.1093/pch/16.2.115 · Cited by 7
“There are concerns regarding the use of TMP/SMX in serious infections because penetration into pus, lungs and thick-walled abscesses is poor, and S aureus may produce sufficient thymidine to inactivate the drug [3].”
BackgroundPrevalence of multidrug resistant Gram-positive cocci in a Chinese hospital over an 8-year period.
Zhang, R., Wang, F., Kang, J., Wang, X., Yin, D., Dang, W., & Duan, J. (2015) · Europe PMC (PubMed Central) · Cited by 6
Role of Trimethoprim-sulfamethoxazole for Treatment of Acute Osteomyelitis in Children
Pezone, I., & Leone, S. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318255ff8d · Cited by 7
Hagihara, M., Kato, H., Uchida, S., Yamashita, R., Tanaka, S., Sakanashi, D., Shiota, A., Asai, N., Koizumi, Y., Suematsu, H., et al. (2019) · Chemotherapy · doi:10.1159/000507540 · Cited by 7
Trimethoprim-Sulfamethoxazole for Osteoarthritis Caused by Staphylococcus aureus or Kingella kingae
Yagupsky, P. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318187a2e7 · Cited by 6
Susceptibility of Streptococcus pyogenes to Trimethoprim-Sulfamethoxazole
Gelfand, M. S., Cleveland, K. O., & Ketterer, D. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.03329-12 · Cited by 6
“Thymidine may become available to infecting microorganisms from damaged host tissues and bacteria, allowing microorganisms to overcome the metabolic block (5).”
BackgroundResultLogan, L. K., & Toltzis, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00250-8 · Cited by 9
Treatment options for skin and soft tissue infections: ‘oldies but goldies’
Ünal, S. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70545-x · Cited by 6
Chhabra, S., Newman, J. M., Peat, T. S., Fernley, R. T., Caine, J. M., Simpson, J. S., & Swarbrick, J. (2010) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309110010857 · Cited by 5
ZINNER, S. H., & Mayer, K. H. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00034-5 · Cited by 8
Trimethoprim, Co-Trimoxazole (Co-T) and Related Agents
Turnidge, J. D. (2010) · CRC Press eBooks · doi:10.1201/b13787-95 · Cited by 4
49th ICAAC Annual Meeting: optimization of anti-infective use in the clinical setting
Yeh, R. F., Jain, R., & Palmer, H. R. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.106 · Cited by 4
Metadata
- Authors
- Goldstein, E. J. C., & Proctor, R. A.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Proctor, R. A.
- ORCID
- Proctor, R. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-15
- Volume
- 46
- Issue
- 4
- Pages
- 584-593
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2087260740
- Semantic Scholar
- f78fb0266126827966c2fc1286d2a500166b4fb5
- Cited by
- 138
- References
- 115
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 6 · 2016: 2 · 2015: 5 · 2014: 14 · 2013: 7 · 2012: 11
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- methicillin-resistant Staphylococcus aureus, trimethoprim-sulfamethoxazole, antifolate, thermonuclease, community-acquired MRSA, multidrug resistance, antibiotic treatment failure, tissue damage
- MeSH terms
- Animals, Anti-Infective Agents, Humans, Staphylococcal Infections, Staphylococcus aureus, Trimethoprim, Sulfamethoxazole Drug Combination, Methicillin Resistance, Community-Acquired Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.